Sublingual Immunotherapy with a Five-Grass Pollen Tablet in Adult Patients with Allergic Rhinitis: An Open, Prospective, Noninterventional, Multicenter Study

Table 4

Nasal, ocular, and bronchial symptoms of grass pollen allergy during the 2008 grass pollen season (the reference season) and the 2009 season (the first year of SLIT).

Symptoms	Severity	Reference season	Immunotherapy season
		(%)	(%)
Nasal symptoms	All patients with data	570 (100)	570 (100)
	No symptoms	6 (1.1)	119 (20.9)
	Mild	30 (5.3)	300 (52.6)
	Moderate	217 (38.1)	120 (21.1)
	Severe	317 (55.6)	31 (5.4)
Ocular symptoms	All patients with data	566 (100)	566 (100)
	No symptoms	69 (12.2)	228 (40.3)
	Mild	113 (20.0)	241 (42.6)
	Moderate	214 (37.8)	75 (13.3)
	Severe	170 (30.0)	22 (3.9)
Bronchial symptoms	All patients with data	546 (100)	546 (100)
	No symptoms	331 (60.6)	442 (81.0)
	Mild	108 (19.8)	76 (13.9)
	Moderate	82 (15.0)	24 (4.4)
	Severe	25 (4.6)	4 (0.7)

: number of patients; %: percentage of patients.